A-485 and I-CBP112 co-operatively reduce CBP/p300 occupancy at chromatin and the expression of androgen-dependent oncogenes such as MYC and PSA, and synergistically suppress prostate cancer cell proliferation 107. Here, CREBBP is linked to prostate carcinoma.